Edo Vellenga

Q: What Schools Are Affiliated With Edo Vellenga

Edo Vellenga is affiliated with the following schools: University of Amsterdam, Utrecht University, University of Groningen, Leiden University, Harvard University

Edo Vellenga's AcademicInfluence.com Rankings

Edo Vellenga

Computer Science

#4905

World Rank

#5180

Historical Rank

Artificial Intelligence

#1342

World Rank

#1369

Historical Rank

Database

#2077

World Rank

#2184

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Edo Vellenga's Degrees

PhD Computer Science University of Amsterdam
Masters Artificial Intelligence Utrecht University
Bachelors Computer Science University of Amsterdam

Similar Degrees You Can Earn

Why Is Edo Vellenga Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Edo Vellenga's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 (2021) (811)
High-dose daunorubicin in older patients with acute myeloid leukemia. (2009) (754)
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. (2012) (740)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). (2012) (561)
Prognostic index for adult patients with acute myeloid leukemia in first relapse. (2005) (461)
Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics' (2005) (405)
The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery (2016) (360)
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. (2004) (330)
BLUEPRINT to decode the epigenetic signature written in blood (2012) (320)
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. (2008) (309)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. (2010) (285)
Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. (2004) (279)
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. (2009) (272)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. (2010) (272)
EFFECTIVE PROPHYLAXIS WITH ORAL ANTICOAGULANTS AND LOW-DOSE HEPARIN DURING PREGNANCY IN AN ANTITHROMBIN III DEFICIENT WOMAN (1983) (241)
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia (1987) (240)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. (1988) (218)
Cytarabine dose for acute myeloid leukemia. (2011) (215)
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. (2010) (210)
Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. (1987) (202)
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. (1994) (200)
Tissue Distribution of the Death Ligand TRAIL and Its Receptors (2004) (198)
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. (2000) (193)
Independent regulation of M-CSF and G-CSF gene expression in human monocytes. (1988) (193)
Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. (1987) (179)
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. (2008) (168)
In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. (2003) (165)
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. (2006) (163)
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. (2006) (163)
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma (2005) (162)
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. (2002) (161)
Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. (1999) (160)
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts (2000) (156)
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma (2008) (156)
Down-Regulation of E-Cadherin in Human Bronchial Epithelial Cells Leads to Epidermal Growth Factor Receptor-Dependent Th2 Cell-Promoting Activity1 (2007) (154)
Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway (2004) (152)
Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure (2005) (151)
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. (2005) (151)
Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. (1999) (149)
Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. (2009) (148)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. (2008) (144)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial (2018) (144)
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. (2013) (142)
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. (2002) (139)
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. (1997) (137)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. (2010) (133)
Impaired Hematopoietic Stem Cell Functioning After Serial Transplantation and During Normal Aging (2005) (132)
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. (2011) (130)
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? (2006) (130)
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. (2007) (129)
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. (2012) (129)
Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. (1988) (128)
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. (2007) (127)
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years (2014) (126)
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. (1995) (126)
The multifaceted role of autophagy in cancer and the microenvironment (2018) (125)
Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor (2001) (124)
Ser727‐dependent transcriptional activation by association of p300 with STAT3 upon IL‐6 stimulation (2001) (120)
Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis. (2016) (120)
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. (2008) (118)
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. (2007) (117)
Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients (2018) (114)
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial (2014) (113)
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. (2000) (110)
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. (2011) (109)
Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. (1998) (109)
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme (2011) (108)
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. (2012) (108)
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. (2004) (104)
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma (1999) (104)
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age (2007) (104)
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy (1991) (104)
Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia (2005) (103)
Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. (2000) (103)
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. (2019) (103)
Bone marrow dysfunction in chronic heart failure patients (2010) (102)
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. (2007) (102)
Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. (1986) (102)
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. (2006) (101)
MEN2A-RET-induced cellular transformation by activation of STAT3 (2001) (100)
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. (2007) (99)
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. (1998) (98)
A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. (1991) (98)
Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. (2009) (98)
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) (2010) (96)
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. (2010) (96)
Plasma IL‐8 and IL‐6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia (1999) (96)
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. (1996) (95)
Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels (2008) (95)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up (2014) (94)
Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. (1999) (93)
Sequential Activation of Rac-1, SEK-1/MKK-4, and Protein Kinase Cδ Is Required for Interleukin-6-induced STAT3 Ser-727 Phosphorylation and Transactivation* (2001) (93)
Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation. (1996) (93)
Correction of granulocytopenia in Felty's syndrome by granulocyte- macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis (1989) (92)
A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study (1986) (90)
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic Leukemia (2003) (89)
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. (2005) (88)
LIPOPROTEIN ASSOCIATED ISOPROTEINS IN A PATIENT WITH CHOLESTEROL EMBOLI RESULTING IN RENAL FAILURE (1983) (87)
First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) (2008) (87)
Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML (2011) (87)
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. (1982) (86)
eFORGE: A Tool for Identifying Cell Type-Specific Signal in Epigenomic Data (2016) (86)
A Proteomics and Transcriptomics Approach to Identify Leukemic Stem Cell (LSC) Markers* (2012) (86)
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. (2013) (85)
MLL–AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny (2013) (84)
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. (2012) (83)
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? (2004) (82)
The Role of Drug Efflux Pumps in Acute Myeloid Leukemia (2002) (82)
Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. (1990) (81)
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk disease (2003) (81)
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. (2015) (80)
The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. (1993) (80)
Signaling through CD5 Activates a Pathway Involving Phosphatidylinositol 3-Kinase, Vav, and Rac1 in Human Mature T Lymphocytes (1998) (80)
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy (2010) (79)
The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. (1994) (78)
Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. (1992) (78)
IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. (1996) (77)
Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells (2010) (77)
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (2015) (77)
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia (2000) (77)
Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. (1989) (77)
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. (2000) (75)
Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells. (1990) (74)
A genetic and genomic analysis identifies a cluster of genes associated with hematopoietic cell turnover. (2002) (74)
The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis‐inducing stimuli (2003) (74)
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. (2007) (73)
Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1. (1997) (73)
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. (2010) (73)
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research (2005) (72)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. (2017) (71)
Fibroblast Growth Factor‐1 and ‐2 Preserve Long‐Term Repopulating Ability of Hematopoietic Stem Cells in Serum‐Free Cultures (2006) (70)
Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. (2002) (70)
HOMOZYGOUS α2-ANTIPLASMIN DEFICIENCY (1979) (69)
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? (1999) (69)
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD (2011) (69)
Interleukin‐6 promotes the production of interleukin‐4 and interleukin‐5 by interleukin‐2‐dependent and ‐independent mechanisms in freshly isolated human T cells (2002) (69)
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study (2001) (69)
Recombinant human erythropoietin in patients with myelodysplastic syndromes. (1991) (69)
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). (2012) (68)
c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). (2001) (67)
Radionuclide imaging of bone marrow disorders (2010) (67)
G(Anh)MTetra, a natural bacterial cell wall breakdown product, induces interleukin-1 beta and interleukin-6 expression in human monocytes. A study of the molecular mechanisms involved in inflammatory cytokine expression. (1994) (67)
Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial. (2001) (67)
Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death (2006) (67)
A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation (1997) (66)
Autophagy Proteins ATG5 and ATG7 Are Essential for the Maintenance of Human CD34+ Hematopoietic Stem‐Progenitor Cells (2016) (66)
Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. (2018) (66)
The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells. (1995) (66)
Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia (2017) (65)
Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. (2016) (64)
Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line (2003) (64)
Der p, IL-4, and TGF-beta cooperatively induce EGFR-dependent TARC expression in airway epithelium. (2007) (63)
Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. (2001) (61)
Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis (2007) (61)
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies (2005) (61)
Predictive value of early 18F‐fluoro‐deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma (2003) (61)
Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells. (2013) (60)
Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. (2003) (60)
ANTITHROMBIN III DEFICIENCY DURING ASPARAGINASE THERAPY (1980) (60)
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. (2015) (60)
AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. (2009) (60)
Interleukin-4 gene expression in activated human T lymphocytes is regulated by the cyclic adenosine monophosphate-dependent signaling pathway. (1996) (59)
Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. (2007) (58)
STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha. (2005) (58)
Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. (2011) (58)
Long‐term treatment with interferon‐α2b for severe pruritus in patients with polycythaemia vera (1995) (58)
Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation (2017) (57)
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. (2000) (56)
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation (2000) (56)
CBFB–MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia (2014) (56)
Impaired interleukin‐8‐ and GROα‐induced phosphorylation of extracellular signal‐regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia (2005) (55)
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. (2010) (55)
Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature. (1991) (55)
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation (2002) (54)
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy (2011) (54)
HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. (2005) (54)
Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. (2002) (54)
The role of breast cancer resistance protein in acute lymphoblastic leukemia. (2003) (54)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
Regulation of spontaneous and TNF/IFN‐induced IL‐6 expression in two human ovarian‐carcinoma cell lines (1999) (53)
Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. (2004) (53)
Downregulation of Signal Transducer and Activator of Transcription 5 (STAT5) in CD34+ Cells Promotes Megakaryocytic Development, Whereas Activation of STAT5 Drives Erythropoiesis (2008) (52)
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients (2013) (52)
Distinct Trends of DNA Methylation Patterning in the Innate and Adaptive Immune Systems (2016) (51)
Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes. (1993) (51)
Transcriptional and posttranscriptional regulation of the interleukin-4 and interleukin-3 genes in human T cells. (1993) (51)
Procalcitonin: A Diagnostic Marker of Bacterial Infection in Neutropenic Cancer Patients with Fever? (2000) (51)
The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. (2016) (51)
LIF-induced STAT3 signaling in murine versus human embryonal carcinoma (EC) cells. (2002) (50)
Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria (2009) (50)
Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell derived factor-1 induced migration of CD34+ cells from patients with myelodysplasia. (2008) (49)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. (2020) (49)
Prostaglandin E2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal. (1998) (49)
Effects of interleukin-3 after chemotherapy for advanced ovarian cancer (1992) (49)
High Functional P-glycoprotein Activity is More Often Present in T-cell Acute Lymphoblastic Leukaemic Cells in Adults than in Children (2003) (49)
Constitutive NF-κB activation in AML: Causes and treatment strategies. (2016) (49)
Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients (2003) (48)
Constitutive cytoplasmic localization of p21Waf1/Cip1 affects the apoptotic process in monocytic leukaemia (2003) (48)
The TAK1-NF-κB axis as therapeutic target for AML. (2014) (48)
The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis (48)
Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. (1992) (47)
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. (1987) (47)
Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors. (2009) (46)
Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. (1998) (45)
The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. (2006) (43)
Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands (2016) (43)
Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. (2008) (43)
The Ca2+/Calmodulin-dependent Kinase Type IV Is Involved in the CD5-mediated Signaling Pathway in Human T Lymphocytes* (1997) (42)
Mammalian Target of Rapamycin Is Required for Thrombopoietin‐Induced Proliferation of Megakaryocyte Progenitors (2006) (42)
The biology of acute myeloblastic leukemia. (1987) (42)
Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. (2002) (42)
Nitric oxide selectively decreases interferon‐γ expression by activated human T lymphocytes via a cGMP‐independent mechanism (1999) (42)
Convergence of Hypoxia and TGFβ Pathways on Cell Cycle Regulation in Human Hematopoietic Stem/Progenitor Cells (2014) (42)
Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. (1999) (42)
Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. (1982) (41)
The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. (1986) (41)
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes (2017) (41)
Patterns of acute myeloid leukemia colony growth in response to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). (1987) (41)
Endothelial Cells Are Main Producers of Interleukin 8 through Toll-Like Receptor 2 and 4 Signaling during Bacterial Infection in Leukopenic Cancer Patients (2003) (41)
Plant Sterols Cause Macrothrombocytopenia in a Mouse Model of Sitosterolemia* (2008) (40)
The influence of l‐asparaginase therapy on the fibrinolytic system (1984) (40)
The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of the eleven cell lines. (1991) (39)
Inhibition of the Transforming Growth Factor β (TGFβ) Pathway by Interleukin-1β Is Mediated through TGFβ-activated Kinase 1 Phosphorylation of SMAD3 (2005) (39)
p38 MAP Kinase Inhibits Neutrophil Development Through Phosphorylation of C/EBPα on Serine 21 (2009) (39)
Polarized Th1 and Th2 cells are less responsive to negative feedback by receptors coupled to the AC/cAMP system compared to freshly isolated T cells (2003) (39)
Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. (2003) (38)
Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. (1997) (37)
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial (2015) (37)
Intensive versus double intensive therapy in untreated multiple myeloma (2004) (37)
Regulation of p100 (NFKB2) expression in human monocytes in response to inflammatory mediators and lymphokines (1998) (37)
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis (2004) (37)
Renal disease in POEMS syndrome: report on a case and review of the literature. (1994) (36)
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model (2016) (36)
Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells (2009) (36)
Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells. (2006) (35)
Single-Cell STAT5 Signal Transduction Profiling in Normal and Leukemic Stem and Progenitor Cell Populations Reveals Highly Distinct Cytokine Responses (2009) (34)
The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria (1995) (34)
Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature (1997) (34)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Myelodysplasia following paroxysmal nocturnal haemoglobinuria: evidence for the emergence of a separate clone (1994) (33)
Different repopulation kinetics of erythroid (BFU‐E), myeloid (CFU‐GM) and T lymphocyte (TL‐CFU) progenitor cells after autologous and allogeneic bone marrow transplantation (1987) (33)
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. (2013) (33)
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies (2015) (32)
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study (2005) (32)
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. (2010) (32)
Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) (31)
Expansion of normal and leukemic human hematopoietic stem/progenitor cells requires rac-mediated interaction with stromal cells. (2005) (31)
Breast Cancer Resistance Protein (BCRP) in Acute Leukaemia (2004) (31)
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain (2009) (31)
Differential regulation of IL‐6 promoter activity in a human ovarian‐tumor cell line transfected with various p53 mutants: Involvement of AP‐1 (1999) (31)
Down-regulation of GATA1 uncouples STAT5-induced erythroid differentiation from stem/progenitor cell proliferation. (2010) (31)
Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock (2019) (31)
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. (2000) (31)
Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis (2010) (30)
Mast cell growth factor modulates CD36 antigen expression on erythroid progenitors from human bone marrow and peripheral blood associated with ongoing differentiation. (1994) (30)
Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes (2019) (30)
Interferon-gamma enhances the LPS-induced G-CSF gene expression in human adherent monocytes, which is regulated at transcriptional and posttranscriptional levels. (1993) (30)
Interleukin‐4 prevents the induction of G‐CSF mRNA in human adherent monocytes in response to endotoxin and IL‐1 stimulation (1991) (30)
Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation. (2014) (30)
Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. (1994) (30)
Interferon-gamma modulates the lipopolysaccharide-induced expression of AP-1 and NF-kappa B at the mRNA and protein level in human monocytes. (1996) (29)
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. (2005) (29)
RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia. (2003) (29)
High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow (2011) (29)
Interleukin-4 (IL-4) receptor expression on human T cells is affected by different intracellular signaling pathways and by IL-4 at transcriptional and posttranscriptional level. (1992) (29)
Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. (2018) (28)
Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F–FLT–PET study (2011) (28)
Differential redox-regulation and mitochondrial dynamics in normal and leukemic hematopoietic stem cells: A potential window for leukemia therapy. (2019) (28)
The reduced GM‐CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation (2007) (28)
Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate (2012) (28)
CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia (2014) (28)
Differential binding activity of the transcription factor LIL-STAT in immature and differentiated normal and leukemic myeloid cells. (1998) (28)
Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples (2009) (27)
An economic model to assess the savings from a clinical application of haematopoietic growth factors. (1996) (26)
Stem Cell Factor Synergistically Enhances Thrombopoietin‐Induced STAT5 Signaling in Megakaryocyte Progenitors through JAK2 and Src Kinase (2005) (26)
In vitro and in vivo modulation of multi‐drug resistance with amiodarone (1991) (26)
Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-β1 is mediated by caspase-dependent and -independent processes (2002) (26)
HOVON 50/GMMG-HD3-trial: Phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. (2005) (26)
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. (2000) (26)
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1. (2013) (26)
A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects (1996) (25)
Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia. (1999) (25)
In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin. (1989) (25)
Resistance of activated human Th2 cells to NO-induced apoptosis is mediated by gamma-glutamyltranspeptidase. (2001) (25)
Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols. (2006) (25)
Simultaneous expression and regulation of G‐CSF and IL‐6 mRNA in adherent human monocytes and fibroblasts (1991) (25)
F-18 FLT PET: A Noninvasive Diagnostic Tool for Visualization of the Bone Marrow Compartment in Patients With Aplastic Anemia: A Pilot Study (2011) (25)
KRASG12V Enhances Proliferation and Initiates Myelomonocytic Differentiation in Human Stem/Progenitor Cells via Intrinsic and Extrinsic Pathways* (2010) (25)
CD27‐triggering on primary plasma cell leukaemia cells has anti‐apoptotic effects involving mitogen activated protein kinases (2004) (25)
Heat shock proteins and Bcl-2 expression and function in relation to the differential hyperthermic sensitivity between leukemic and normal hematopoietic cells (2007) (24)
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells (2012) (24)
Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. (2011) (24)
Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. (1995) (24)
HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells (2019) (24)
Stem cell factor enhances erythropoietin-mediated transactivation of signal transducer and activator of transcription 5 (STAT5) via the PKA/CREB pathway. (2003) (24)
Altered β2‐adrenergic regulation of T cell activity after allergen challenge in asthma (2004) (24)
Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice. (2003) (24)
The regulation of interleukin 5 and interleukin 3 gene expression in human T cells. (1994) (24)
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. (2018) (24)
Effects of prednisone and splenectomy in patients with idiopathic thrombocytopenic purpura: only splenectomy induces a complete remission (2001) (24)
Effects of overexpression of the SH2-containing inositol phosphatase SHIP on proliferation and apoptosis of erythroid AS-E2 cells (2001) (23)
Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial (2013) (23)
Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHA-DEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients With Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN (2011) (23)
IL-7 enhances the expression of IL-3 and granulocyte-macrophage-CSF mRNA in activated human T cells by post-transcriptional mechanisms. (1993) (23)
Interleukin‐4 suppresses the interleukin‐3 dependent erythroid colony formation from normal human bone marrow cells (1990) (23)
Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. (2004) (23)
Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma (2009) (22)
Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis (2019) (22)
α-interferon for intractable pruritus in polycythaemia vera (1991) (22)
An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. (2000) (22)
The supportive effects of IL-7 on eosinophil progenitors from human bone marrow cells can be blocked by anti-IL-5. (1992) (22)
cAMP/PKA-mediated Regulation of Erythropoiesis (2003) (22)
Central diabetes insipidus preceding acute myeloid leukemia with t(3;12)(q26;p12). (2000) (22)
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach (2018) (22)
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial (2019) (22)
Exposure to TARC alters beta2-adrenergic receptor signaling in human peripheral blood T lymphocytes. (2005) (22)
Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. (2017) (21)
Activation of the cAMP-dependent signaling pathway downregulates the expression of interleukin-3 and granulocyte-macrophage colony-stimulating factor in activated human T lymphocytes. (1996) (21)
Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells. (2005) (21)
Interleukin-4 and its receptor; modulating effects on immature and mature hematopoietic cells. (1993) (21)
Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. (2003) (21)
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. (2010) (20)
Differential effects of interleukin-3 and interleukin-1 on the proliferation and interleukin-6 protein secretion of acute myeloid leukemic cells; the involvement of ERK, p38 and STAT5. (1999) (20)
Interleukin-4 receptor regulation in human monocytic cells. (1994) (20)
Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. (1992) (19)
The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients. (1996) (19)
Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM) (2008) (19)
Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway. (2005) (19)
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy (2018) (19)
RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs. (2019) (19)
Interleukin-4 mRNA and protein in activated human T cells are enhanced by interleukin-7. (1994) (18)
Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. (1998) (18)
G(AnH)MTetra, a naturally occurring 1,6-anhydro muramyl dipeptide, induces granulocyte colony-stimulating factor expression in human monocytes: a molecular analysis (1994) (18)
The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia. (2009) (18)
The effects of IL-1 beta and IL-4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells. (1992) (18)
Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells (2009) (18)
CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia (2013) (18)
Decreased Affinity of Recombinant Human Tumor Necrosis Factor-related Apoptosis-inducing Ligand (rhTRAIL) D269H/E195R to Osteoprotegerin (OPG) Overcomes TRAIL Resistance Mediated by the Bone Microenvironment (2013) (17)
The effects of IL‐1 and IL‐4 on the Epo‐independent erythroid progenitor in polycythaemia vera (1994) (17)
Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating potential, and sensitivity toward hyperthermic purging in mice mobilized with cyclophosphamide and granulocyte colony-stimulating factor. (2002) (17)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. (2021) (17)
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
A study of the cellular and humoral immune response in patients with myelofibrosis. (2008) (17)
Inhibition of the transforming growth factor beta (TGFbeta) pathway by interleukin-1beta is mediated through TGFbeta-activated kinase 1 phosphorylation of SMAD3. (2005) (16)
Prophylaxis of thrombosis in antithrombin III-deficient women during pregnancy and delivery. (1984) (16)
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology (2015) (16)
Differential regulation of M‐CSF and IL‐6 gene expression in monocytic cells (1994) (16)
CD34+/CD36− cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation (1998) (16)
Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation (2016) (16)
Sensitivity of IL‐5 production to the cAMP‐dependent pathway in human T cells is reduced by exogenous IL‐2 in a phosphoinositide 3‐kinase‐dependent way (2003) (16)
Expression and regulation of IL-4 receptors on human monocytes and acute myeloblastic leukemic cells. (1991) (16)
Disturbed granulocyte macrophage‐colony stimulating factor priming of phosphatidylinositol 3,4,5‐trisphosphate accumulation and Rac activation in fMLP‐stimulated neutrophils from patients with myelodysplasia (2004) (16)
Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells (2012) (15)
Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria (2001) (15)
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial (2017) (15)
Thrombotic Complications During L-Asparaginase Related to Protein C Deficiency? (1985) (15)
Co‐expression of CD30 ligand and interleukin 4 (IL‐4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL‐4‐producing CD30+ normal T cells (2002) (15)
Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. (2012) (15)
BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells (2017) (14)
Effects of hematopoietic growth factors on chemotherapy-induced myelosuppression. (1992) (14)
Quantitation of Plasma Levels of Tetranectin - Effects of Oral Contraceptives, Pregnancy, Treatment with L-Asparaginase and Liver Cirrhosis (1989) (14)
Interferon treatment in polycythaemia vera. (1996) (14)
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases (2010) (14)
The happy destiny of frozen haematopoietic stem cells: from immature stem cells to mature applications. (2004) (14)
PET in Benign Bone Marrow Disorders. (2017) (14)
Loss of quiescence and impaired function of CD34+/CD38low cells one year following autologous stem cell transplantation (2013) (14)
Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation (2012) (14)
Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2 (2015) (14)
Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis (2000) (14)
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (14)
The Role of Oral Mucositis on the Systemic Inflammation Parameter IL-8 in Febrile Neutropenic Cancer Patients (2006) (14)
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. (1996) (14)
Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network (2013) (14)
S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS) (2019) (13)
Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients (2015) (13)
Interleukin‐6 production by activated human monocytic cells is enhanced by MK‐571, a specific inhibitor of the multi‐drug resistance protein‐1 (1999) (13)
Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells. (2016) (13)
Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH3 (2000) (13)
Effect of Ciclesonide Treatment on Allergen-Induced Changes in T Cell Regulation in Asthma (2007) (13)
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia (2018) (13)
Correction of neutropenia by GM-CSF in patients with a large granular lymphocyte proliferation (1992) (13)
Bcl-xl expression in multiple myeloma (2005) (13)
Constitutive activation of NF-kappa B is not sufficient to disturb normal steady-state hematopoiesis. (2006) (13)
ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML (2014) (13)
A possible role for spontaneous interleukin-8 production by acute myeloid leukemic cells in angiogenesis related processes: work in progress. (2001) (13)
Interleukin-7 Upregulates the Interleukin-2–Gene Expression in Activated Human T Lymphocytes at the Transcriptional Level by Enhancing the DNA Binding Activities of Both Nuclear Factor of Activated T Cells and Activator Protein-1 (1997) (13)
A016 Donor Versus No-Donor Analysis of Newly Diagnosed Myeloma Patients included in the HOVON-50/54 Study (2009) (12)
Constitutive activation of NF-κB is not sufficient to disturb normal steady-state hematopoiesis (2006) (12)
Convergence Of Hypoxia and TGF beta Pathways On Cell Cycle Regulation In Human Hematopoietic Stem/Progenitor Cells (2013) (12)
CITED2 affects leukemic cell survival by interfering with p53 activation (2016) (12)
Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. (2003) (12)
CITED 2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia (2014) (12)
Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial. (2016) (12)
Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models (2016) (12)
Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting (2016) (12)
Myeloma clonotypic B cells are hampered in their ability to undergo B‐cell differentiation in vitro (2002) (12)
Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells (2009) (12)
New Vessel Formation and Aberrant VEGF/VEGFR Signaling in Acute Leukemia: Does it Matter? (2002) (11)
Heterogeneity in the Multiple Myeloma Tumor Clone (2004) (11)
ENDOTOXIN IN PAROXYSMAL NOCTURNAL HAEMOGLOBULINURIA (PNH) (1982) (11)
Characterization of the erythropoiesis in myelodysplasia by means of ferrokinetic studies, in vitro erythroid colony formation and soluble transferrin receptor (1998) (11)
Plasma beta-thromboglobulin in normal pregnancy and pregnancy-induced hypertension. (1983) (11)
Interaction between nitric oxide and subsets of human T lymphocytes with differences in glutathione metabolism (2002) (11)
interleukin-6 release and flare-up of the arthritis macrophage colony-stimulating factor. Simultaneous induction of Correction of granulocytopenia in Felty's syndrome by granulocyte- (2011) (11)
Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome. (2004) (11)
Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients. (2019) (11)
SUCCESSFUL IMMUNOSUPPRESSIVE TREATMENT AFTER FAILURE OF ERYTHROPOIETIN THERAPY IN TWO SUBJECTS WITH REFRACTORY ANAEMIA (1993) (11)
Cryptococcal cerebellitis after chemotherapy and autologous stem cell re-infusion in a patient with multiple myeloma (2009) (10)
Ectopic expression of C/EBPα and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia (2009) (10)
Normal levels of antithrombin III in acute leukemia complicated by coagulopathy. (1980) (10)
Familial Multiple Myeloma: Report on Two Families and Discussion of Screening Options (2007) (10)
University of Groningen Constitutive cytoplasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia Schepers, (2003) (10)
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy (2018) (10)
Alpha-interferon for intractable pruritus in polycythaemia vera. (1991) (10)
Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum. (1993) (10)
Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. (2005) (10)
Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by 18F-FLT PET scanning (2011) (10)
Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive (2018) (10)
Effective targeting of primitive AML CD34+ cells by the second‐generation proteasome inhibitor carfilzomib (2015) (10)
In vitro megakaryocyte expansion in patients with delayed platelet engraftment after autologous stem cell transplantation (2002) (9)
Cytogenetic analysis of cryopreserved bone marrow cells. (2001) (9)
Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions. (2016) (9)
THE MUTUAL RELATION BETWEEN THE 2 MOLECULAR-FORMS OF ALPHA-2-ANTIPLASMIN IN BLOOD (1983) (9)
Identification of quantitative trait loci regulating haematopoietic parameters in B6AKRF2 mice (2006) (9)
Proteolytic degradation of Smad4 in extracts of AML blasts. (2002) (9)
Role of macrophage colony-stimulating factor in the differentiation and expansion of monocytes and dendritic cells from CD34+ progenitor cells (1999) (9)
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis (2020) (8)
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens (2018) (8)
Divergent effects of IL-10 and IL-4 on the proliferation and growth factor secretion by acute myeloblastic leukemic cells. (1995) (8)
Sinusoidal endothelial cells are damaged and display enhanced autophagy in myelodysplastic syndromes (2013) (8)
INTERLEUKIN-4-MEDIATED INHIBITION OF C-FOS MESSENGER-RNA EXPRESSION - ROLE OF THE LIPOXYGENASE DIRECTED PATHWAY (1994) (8)
Platelet production rate predicts the response to prednisone therapy in patients with idiopathic thrombocytopenic purpura (2007) (8)
Gene expression, biological effects and clinical aspects of lymphokines. (1997) (8)
Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) (2017) (8)
Erythroid progenitors in polycythemia vera demonstrate a different response pattern to IL-4 compared to the normal BFU-E from peripheral blood. (1991) (8)
Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) (2017) (8)
Acute-phase response in patients given rhIL-3 after chemotherapy (1992) (8)
Immunological dysfunction in paroxysmal nocturnal haemoglobinuria. (1981) (8)
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma (2016) (8)
Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016 (2018) (8)
Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols. (2004) (8)
Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia (2017) (8)
Resistance of activated human Th 2 cells to NO-induced apoptosis is mediated by γ-glutamyltranspeptidase (2001) (7)
Vascular proliferation as an unusual cause of hemorrhagic diathesis in myelofibrosis. (1991) (7)
Mobilized Human CD 34 Hematopoietic Stem Cells Enhance Tumor Growth in a Nonobese Diabetic / Severe Combined Immunodeficient Mouse Model of Human Non-Hodgkin ’ s Lymphoma 1 (2001) (7)
Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM) (2008) (7)
Long-term maintenance of human hematopoietic stem/progenitor cells (2008) (7)
Therapeutic options in systemic AL amyloidosis. (2004) (7)
The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines (1997) (7)
Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice. (2002) (7)
Evaluation assays measuring platelet kinetics in bone marrow and peripheral blood. An overview. (2002) (7)
Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial (2017) (7)
Combined HAT/EZH2 modulation leads to cancer-selective cell death (2018) (7)
Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon gamma. (2001) (6)
First Interim Analysis of HOVON 76: Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma (2009) (6)
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests (2000) (6)
B152 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) (2009) (6)
EVALUATING THE LONG-TERM EFFICACY OF ROMIPLOSTIM (AMG 531) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DURING AN OPEN-LABEL EXTENSION STUDY (2008) (6)
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. (2005) (6)
Is FDG PET a Better Imaging Tool Than Somatostatin Receptor Scintigraphy in Patients With Relapsing Multiple Myeloma? (2012) (6)
18F-FDG PET Increases Visibility of Bone Lesions in Relapsed Multiple Myeloma: Is This Hypoxia-Driven? (2015) (6)
Treatment strategies in acute myeloid leukemia. (2011) (6)
Mutual interactions between p53 and growth factors in cancer. (1998) (6)
Extramedullary haematopoiesis imaging with 18F-FLT PET (2010) (6)
Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma (2010) (5)
CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax (2019) (5)
Incidence, Outcome and Risk Factors of Pseudotumor Cerebri after All- Trans Retinoic Acid and Anthracycline-Based Chemotherapy in Patients with Acute Promyelocytic Leukemia (2008) (5)
Glycocalicin index is elevated in ITP patients with a decreased platelet production rate in the platelet kinetic studies. (2001) (5)
Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma (2010) (5)
Rapid progression into S-phase of quiescent stem cells after chemotherapy (2003) (5)
Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia. (2019) (5)
Identification of HIF 2 as an important STAT 5 target gene in human hematopoietic stem cells (2011) (5)
Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups. (2009) (5)
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update (2012) (5)
Long-term repopulating ability of hematopoietic stem cells requires functional expression of Fibroblast Growth Factor-receptors (2002) (5)
Title : Modeling BCR-ABL and MLL-AF 9 leukemia in a human bone marrow-like 1 scaffold based xenograft model 2 3 (2016) (4)
Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program (2011) (4)
Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia (1997) (4)
Nucleophosmin analysis in acute myeloid leukemia from a single center: value of combining immunohistochemistry with molecular mutation analysis (2013) (4)
Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis (2008) (4)
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib (2012) (4)
Phase III efficacy study of interleukin‐3 after autologous bone marrow transplantation in patients with malignant lymphoma (1999) (4)
PROGNOSTIC IMPACT OF WHITE BLOOD CELL COUNT IN INTERMEDIATE RISK AML (2011) (4)
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS (2021) (4)
Fibronectin-complex (FN-C) present in normal plasma. (1985) (4)
Ischaemic colitis and lung infiltrates caused by extramedullary haematopoiesis in a patient with an acute erythroid leukaemia following polycythaemia vera. (1998) (4)
High-Dose Therapy in AL Amyloidosis : A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON) (2008) (4)
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols (2019) (4)
Erythroid progenitors from patients with low-risk myelodysplastic syndromes are dependent on the surrounding micro environment for their survival. (2015) (4)
A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis (2013) (4)
Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. (2021) (4)
Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (2020) (4)
Interleukin-4-mediated inhibition of C-Fos mRNA expression: role of the lipoxygenase directed pathway. (1994) (4)
PLASMA FIBRONECTIN IN IDIOPATHIC MYELOFIBROSIS (1985) (4)
The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. (1995) (4)
Fanconi anaemia presenting as acute myeloid leukaemia and myelodysplastic syndrome in adulthood: a family report on co‐occurring FANCC and CHEK2 mutations (2019) (4)
Vascular problems in paroxysmal nocturnal haemoglobinuria (1982) (4)
Recombinant erythropoietin failed to correct anemia in Fanconi syndrome. (1989) (4)
Risk-adapted treatment of acute promyelocytic leukemia: Updated results of the Spanish PETHEMA LPA99 Trial using ATRA and anthracycline monochemotherapy (2005) (3)
DEFICIENCY OF ALPHA-2-PLASMIN INHIBITOR AND HEMORRHAGIC DIATHESIS (1980) (3)
High expression of multidrug resistance-associated proteins predicts prognosis in acute lymphoblastic leukemia in children and adults. (2004) (3)
A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease (2020) (3)
P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia. (1999) (3)
Cytokines and Growth Factors in Blood Transfusion (1997) (3)
Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. (2019) (3)
Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results. (2005) (3)
Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (2019) (3)
Outcome of a hybrid chemotherapy regimen with mediastinal irradiation in leukemic T-lymphoblastic lymphoma. (1995) (3)
Interpretation of inflammatory markers in feverish cancer patients with or without neutropenia at admission (2001) (3)
Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (>60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t) (HOVON 97 AML study) (2008) (3)
Hematopoietic Growth Factors (1990) (3)
On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) (2021) (3)
Erratum in Schepers et al. Reintroduction of C/EBPα in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. (2007) (3)
Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia (2020) (3)
[The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma]. (1991) (3)
Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up (2019) (3)
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation (2021) (3)
Abstracts of papers and posters (2005) (3)
Breakpoint analysis by fluorescence in situ hybridization in myelodysplastic syndromes with t(3;12)(q26;p13) and expression of EVI1 (2000) (3)
6-mercaptopurine for AML patients not eligible for aggressive remission induction. (1997) (2)
Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission (2014) (2)
Novel treatments for systemic amyloidosis (2009) (2)
Signaling through CD5 activates a pathway involving PI 3-kinase, Vav and Rac1 in human mature T lymphocytes. (1997) (2)
Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells. (2019) (2)
Effects of Recombinant Human Interleukin-6 in Cancer Patients : A Phase 1-11 Study (2002) (2)
Polymorphisms and lack of or aberrant expression of HLA class I and II may influence antigen presentation in classical Hodgkin lymphoma. (2005) (2)
A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) (2001) (2)
Para-apoptosis of the megakaryocytic progenitors contributes to the thrombocytopenia in patients with ITP. (2001) (2)
Activity and expression of the multidrug resistance protein MRP1 and MRP2 in acute myeloid leukemia (AML) cells. (1997) (2)
PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (1983) (2)
Criteria for complete remission in acute myeloid leukemia revisited. (2003) (2)
VP-16-mediated cytotoxicity is modulated by interleukin-3 in a growth factor-dependent leukemic cell line. (1994) (2)
PRETREATMENT WITH THALIDOMIDE AND BORTEZOMIB DOES NOT INFLUENCE RESPONSE TO LENALIDOMIDE IN RELAPSED MYELOMA. PRELIMINARY RESULTS FROM PATIENTS INCLUDED IN DUTCH COMPASSIONATE NEED PROGRAMME (2008) (2)
Transcriptional regulation of interleukin-6 gene expression in acute myeloid leukemia blasts with constitutive cytokine production (1996) (2)
Influence of Different Dosages of Cyclophosphamide on Stem Cell Mobilization and Engraftment In Newly Diagnosed Multiple Myeloma Patients Treated with a Thalidomide Containing Regimen (2010) (2)
Constitutive cytoplasmic localisation of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukemia. (2002) (2)
Identification of transcriptional networks affecting hematopoietic stem cell function using "genetical genomics". (2003) (2)
Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma (2014) (2)
IPT score at relapse or progression is highly predictive for outcome after autologous stem cell transplantation in chemosensitive NHL. (2002) (2)
Targeted RNA-Sequencing Enables Detection of Relevant Translocations and Single Nucleotide Variants and Provides a Method for Classification of Hematological Malignancies-RANKING. (2020) (2)
A genetical genomics approach to identify transcriptional pathways in hematopoietic stem cells (2003) (2)
The significance of the aminoterminal propeptide of type III procollagen in paroxysmal nocturnal haemoglobinuria and myelofibrosis (2004) (2)
INTERLEUKIN-7 ENHANCES CYTOKINE EXPRESSION IN ACTIVATED HUMAN T-CELLS (1993) (2)
The Expression and Regulation of G-CSF and GM-CSF (1996) (2)
Establishing Human Niche Xenograft Models for Myeloid and Lymphoid Leukemia Driven By MLL-AF9 (2013) (2)
Genetic Screening Test to Detect Translocations in Acute Leukemias by Use of Targeted Locus Amplification. (2018) (2)
High functional activity of P-glycoprotein is an independent prognostic factor for poor treatment outcome in T-cell acute lymphoblastic leukemia. (2001) (2)
Lymphocyte subpopulations in peripheral blood and bone marrow in patients with idiopathic myelofibrosis (1987) (1)
Overexpression of Oncogenic KRAS G12V in Human Stem and Progenitor Cells Enhances Proliferation and Initiates Monocytic Differentiation Via Intrinsic and Extrinsic Pathways (2009) (1)
F-18-FLT is an excellent tool to visualize the bone marrow compartment in patients with aplastic anemia (2009) (1)
MAST-CELL GROWTH-FACTOR (MFG) SUPPORTS ERYTHROID COLONY FORMATION IN POLYCYTHENIA VERA (PV) IN THE PRESENCE AND ABSENCE OF SERUM AND ERYTHROPOIETIN (EPO) (1993) (1)
Serum of anaemic heart failure patients inhibits haematopoiesis (2005) (1)
Blinded mid-treatment FDG-PET in newly diagnosed aggressive Non-Hodgkin lymphoma (NHL) : First results of a prospective multicenter study. (2006) (1)
Cell-Promoting Activity Growth Factor Receptor-Dependent Th2 Bronchial Epithelial Cells Leads to Epidermal Down-Regulation of E-Cadherin in Human (2011) (1)
Acute lymphoblastic leukemia: Single center experience with modified chemotherapy. (1995) (1)
Central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and reinforced anthracycline monochemotherapy (2007) (1)
Latent EBV infection of Hodgkin Reed-Sternberg cells predicts adverse outcome in older adult classical Hodgkin lymphoma patients (2007) (1)
Knockdown of TP53 in ASXL1 negative background rescues apoptotic phenotype of human hematopoietic stem and progenitor cells but without overt malignant transformation (2017) (1)
CD27 is heterogeneously expressed on myeloma plasma cells and inhibits dexamethasone induced apoptosis. (2001) (1)
ALTERNATIVE APPROACHES TO HUMAN BLOOD RESOURCES IN CLINICAL PRACTICE (1998) (1)
Effect of Ultrafilterable Platinum Concentration on Cisplatin and Carboplatin Cytotoxicity in Human Tumor and Bone Marrow Cells in Vitro (1994) (1)
Secondary acute myeloid leukemia and myelodysplastic syndromes following ATRA and anthracycline monochemotherapy treatment for acute promyelocytic leukemia (2007) (1)
HOVON 50/GMMG-HD3-trial (2005) (1)
2 affects leukemic cell survival by interfering with p 53 activation (2017) (1)
Effects of protein phosphatase inhibitors okadaic acid and diamide on ERK, JNK1 and p38 kinases involved in IL-6 expression in human monocytes. (1997) (1)
cells from patients with myelodysplasia + migration of CD34 contributes to an impairment of stromal cellderived factor-1induced Reduced activation of protein kinase B, Rac, and F-actin polymerization (2009) (1)
Targeting Autophagy As a Potential Therapeutic Strategy for the Treatment of AML (2015) (1)
Nucleophosmin analysis in acute myeloid leukemias from a single center: discordances between immunohistochemistry on formalin fixed biopsies and molecular mutation analysis (2013) (1)
USP7 as part of non-canonical PRC1.1 is a druggable target in leukemia (2019) (1)
A ‘pre‐induction course’ with non‐cross‐reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia (2007) (1)
The role of colony-stimulating factors in acute leukemia (2005) (1)
Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34(+)/CD38(low) Cells One Year Following Autologous Stem Cell Transplantation (2011) (1)
Congenital deficiencies in α2-antiplasmin (1984) (1)
predict prognosis in normal karyotype AML (2013) (1)
Transcription factor dosage (2007) (1)
Platelet kinetic studies in patients diagnosed as idiopathic thrombocytopenic purpura (ITP) (1998) (1)
Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study (2014) (1)
Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial (2013) (1)
BRD 3 / 4 inhibition and FLT 3-ligand deprivation target pathways that are essential for the survival of human MLL-AF 9 + leukemic cells (2017) (1)
Allogeneic Hematopoietic-Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40-60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning (2011) (1)
Heterogeneity in Simvastatin-Induced Cytotoxicity in AML Is Related to Differential Ras-Isoprenylation, Rather Than to Blockade of Cholesterol Synthesis. (2009) (1)
Influence of genetic single nucleotide Polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and treatment related toxicity in patients with multiple myeloma treated in the HOVON 24 trial. (2005) (1)
Decreased affinity of rhTRAIL D269H/E195R to OPG overcomes TRAIL-resistance mediated by the bone microenvironment (2015) (1)
INTERFERON-GAMMA MODULATES THE LIPOPOLYSACCHARIDE-INDUCED EXPRESSION OF AP-1 AND NF-KAPPA B AT MESSENGER-RNA AND PROTEIN LEVEL IN HUMAN MONOCYTES (1994) (1)
Interpretation of inflammatory markers in feverish cancer patients with or without neutropenia at admission. (2001) (1)
Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA). (2004) (1)
Autologous stem cell transplantation induces a phenotypical shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by 18F-FLT PET scanning (2013) (1)
MAST-CELL GROWTH-FACTOR MODULATES CD36 ANTIGEN EXPRESSION ON ERYTHROID PROGENITORS WHICH IS ASSOCIATED WITH ONGOING DIFFERENTIATION (1993) (1)
Risk-adapted treatment of acute promyeliacytic leukemia : Updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy (2007) (1)
Diathesis in a Dutch Family: An Inherited Deficiency of a2-Antiplasmin (2011) (1)
Measurable regression of systemic light chain (AL) amyloid in fat tissue after a response of amyloidogenic free light chain in serum (2011) (1)
Gene Expression Profiling In Leukemic Stem Cell-Enriched AML CD34+ Cell Fraction Identifies Target Genes That Predict Prognosis In Normal Karyotype AML (2010) (1)
CHAPTER 3 Downregulation of MEIS 1 impairs long-term expansion of CD 34 + NPM 1-mutated acute myeloid leukemia cells (2013) (1)
RUNX1 Mutations Lead to a Myeloid Differentiation Block in Association with Enhanced Proliferation By Altering the RUNX1 Transcriptional Program (2017) (1)
Transcription factor dosage: Maximal STAT5-induced proliferation and stem cell self-renewal at intermediate STAT5 activity levels (2007) (1)
RECURRENT INTESTINAL HEMORRHAGES CAUSED BY A LIPOMA IN THE ILEOCECAL VALVE IN A PATIENT WITH VONWILLEBRANDS DISEASE (1980) (1)
Blocking the Autophagy Pathway As Potential Target for the Treatment of Wild Type P53 AMLs (2016) (1)
Mouse Versus Human Extrinsic Cues Dictate Transformation Potential In BCR-ABL/BMI1-Induced Leukemia In Humanized Xenograft Models (2013) (1)
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma. (2009) (1)
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin lymphoma (2007) (1)
[Mycoplasma pneumoniae as a possible cause of pericarditis]. (1983) (1)
Expression and activity of breast cancer resistance protein (BCRP) in acute lymphoblastic leukemia. (2002) (1)
Genetical genomics to identify gene networks in hematopoietic stem cells (2005) (1)
Randomized placebo controlled trial of GM-CSF in patients with chemotherapy related febrile neutropenia (1995) (1)
THE INFLUENCE OF CROSSLINKING BY FACTOR-XIII ON LYSIS OF WHOLE AND DILUTED BLOOD-CLOTS - AVOIDANCE OF INTERFERENCE BY ANTI-COAGULANT AND ROLE OF ALPHA-2-ANTIPLASMIN (1983) (1)
Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for (2011) (1)
University of Groningen ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML Capala, (2014) (0)
Authors' reply (1986) (0)
Author response: Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock (2019) (0)
Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy : Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission (2010) (0)
Influence of prophylactic cytokine treatment on haematopoietic stem cells before cytotoxic treatment (1998) (0)
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study (2022) (0)
91 Ferrokinetic studies in myelodysplasia suggests a dissociation of proliferation and differentiation in erythropoiesis (1997) (0)
Matrix metalloproteinases : Do MMP-2 and MMP-9 play a role in acute myeloid leukemia? (2003) (0)
Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse. (2009) (0)
Convergence of TGFb and IL-1 signaling pathways: Inhibition of SMAD3 transcriptional activity by TAK1: Inhibition of SMAD3 transcriptional activity by TAK1. (2003) (0)
CD34(+)/CD36(-) cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to erythropoietin and mast cell growth factor (1998) (0)
The role of fibroblast growth factor-1 and its receptor, Fgfr-1, in the regulation of normal and malignant haematopoietic stem cell numbers (2000) (0)
dependent mechanism stimulate monocyte cytotoxicity through a tumor necrosis factor- Human granulocyte-monocyte colony-stimulating factor and interleukin 3 (2011) (0)
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma (2010) (0)
scan in patients with relapsing multiple myeloma; a feasibility study (2012) (0)
by expression of BMI1 Long-term maintenance of human hematopoietic stem/progenitor cells (2012) (0)
Using a lentiviral Tet-regulated miR-E shRNA dual color vector to evaluate gene function in human leukemic stem cells in vivo (2019) (0)
No increase of apoptosis can be observed in bone marrow histology by TUNEL and electron microscopy in myelodysplasia patients (1998) (0)
Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support (2016) (0)
FLT-PET in Haematological Disorders: A Novel Technique To Analyze the Proliferative Activity of the Bone Marrow Compartment. (2006) (0)
mice increases donor cell engraftment after bone marrow transplantation in Growth factor treatment prior to low-dose total body irradiation (2014) (0)
Cytokines and Cell Mediated Immunology (1993) (0)
Acute lymphocytic leukaemia complicated by hypofibrinogenaemia without evidence for impaired fibrinogen synthesis or disseminated intravascular coagulation. (1983) (0)
A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials (2017) (0)
comparison of French-Belgian-Swiss and PETHEMA results Treatment of newly diagnosed acute promyelocytic leukemia (APL): a (2013) (0)
Molecular analysis and biological implications of STAT 3 signal transduction (2001) (0)
Ex vivo expansion of megakaryocytic cells from peripheral blood stem cells. (1998) (0)
Disturbed priming of phosphatidylinositol 3,4,5-triphosphate accumulation and rac activation in neutrophils from patients with myelodysplasia. (2003) (0)
HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells (2019) (0)
Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat (2019) (0)
Different isotype expression by clonally related post-germinal center B cells in multiple myeloma patients (1997) (0)
Improved survival by allogeneic haematopoietic stem cell transplantation versus autologous HSCT or chemotherapy as consolidation therapy in AML CR1 patients aged 40-60 years (2012) (0)
IN-VITRO GROWTH-BEHAVIOR OF ACUTE MYELOID LEUKEMIC-CELLS (1994) (0)
A285 The Dutch Lenalidomide Named Patient Program: Results and Feasibility in Heavily Pretreated Patients (2009) (0)
Involvement of lipid rafts in impaired fMLP-stimulated ROS production of GM-CSF-primed neutrophils from patients with myelodysplasia. (2005) (0)
Prognostic Value of Immunophenotype Analysis in Patients with Acute Promyelocytic Leukemia (APL) Treated with All-Transretinoic Acid and Anthracyclin Monochemotherapy. (2006) (0)
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (0)
Resource Distinct Trends of DNAMe thylation Patterning in the Innate and Adaptive Immune Systems Graphical Abstract Highlights (2016) (0)
HEMATOPOIETIC GROWTH-FACTORS IN DRUG-INDUCED AGRANULOCYTOSIS - REPLY (1995) (0)
Oncogenic Ras blocks TGF-beta-induced cell-cycle arrest by regulation of p27 through a MEK/ERK-dependent pathway (2003) (0)
Single injections of cytotoxic drugs induce long-term in vivo activation of the murine hemopoietic stem cell compartment. (1997) (0)
Selective expression of a number of ABC transporter genes in normal CD34(+)CD38(-) versus CD34(+)CD38(-) cells, with a reverse pattern in a subgroup of AML patients. (2004) (0)
The LILRE binding site of LIL-STAT binds phosphorylated STAT1 and STAT3 dependent on IFN-gamma or IL-6 stimulation. (2000) (0)
Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens (2013) (0)
NF-KB AND MCL-1 ARE IMPORTANT DETERMINANTS FOR THE EFFECTIVENESS OF BORTEZOMIB IN AML CD34+CELLS (2012) (0)
Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis (2019) (0)
Factors involved in megakaryocyte development. (2006) (0)
Tranforming growth factor beta 1 downregulates thrombopoietin-induced mitogen-activated protein kinase Erk and Erk-dependent STAT3 signalling pathways in MO7e cells (2002) (0)
3035 – THE IL1-IL1RAP AXIS PLAYS AN IMPORTANT ROLE IN THE INFLAMMATORY LEUKEMIC NICHE THAT FAVORS ACUTE MYELOID LEUKEMIA CELL PROLIFERATION OVER NORMAL HEMATOPOIESIS (2020) (0)
Inappropriate interaction between TGF-beta and IL-6 signal transduction in AML (2000) (0)
The involvement of NPM mutations and E-Cadherin in the development of AML (2006) (0)
62 MUTATIONS IN EPIGENETIC REGULATORS ARE SIGNIFICANTLY ASSOCIATED WITH ABERRANT EXPRESSION OF MYELOID DIFFERENTIATION ANTIGENS ON MYELOID PROGENITOR CELLS IN LOW/INTERMEDIATE RISK MDS (2015) (0)
monocytes Independent regulation of M-CSF and G-CSF gene expression in human (2011) (0)
Gene expression in activated human T-lymphocytes is regulated by the camp dependent signaling pathway (1995) (0)
Autologous peripheral blood stem cell grafts are largely contaminated with malignant hematopoietic precursors despite repeated cycles of intensive chemotherapy. (1998) (0)
Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial (2020) (0)
GENETIC VARIATIONS ASSOCIATED WITH TREATMENT RESPONSE, PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA IN THE HOVON 50/GMMG-HD3 TRIALS (2010) (0)
Cell Reports Resource Distinct Trends of DNAMethylation Patterning in the Innate and Adaptive Immune Systems (2017) (0)
Mesenchymal Stem Cells from Patients 1 Year Following Autologous Stem Cell Transplantation Have a Pro-Inflammatory and Senescent Phenotype Compromising the Support of Hematopoietic Stem Cells (2014) (0)
Visibility Of Bone Lesions In Relapsed Multiple Myeloma Can Be Improved By FDG-PET Scanning (2013) (0)
The phosphatidylinositol 3-kinase pathway has a different function in immature versus mature hematopoietic cells. (1999) (0)
Genetic fine-mapping and characterization of mutations of genes in the HLA region that predispose or protect for the development of EBV-positive and -negative subtypes of classical Hodgkin's lymphomas (2000) (0)
In vitro growth behaviour of acute myeloid leukaemic cells. (1994) (0)
Il-8 Plasma Levels Can Define A Low Risk Group Of Patients With Fever and Chemotherapy-Related Neutropenia (1999) (0)
THE MOLECULAR PATHWAYS AFFECTED BY THE AML ASSOCIATED ONCOFUSION PROTEINS AML1-ETO AND PML-RAR (2010) (0)
Evidence for profound bone marrow dysfunction in chronic heart failure patients (2009) (0)
Efficacy of antithymocyte globulin as first-line treatment for aplastic anemia—a single-center experience (2018) (0)
Serum Levels of Free Kappa and Lambda Light Chains in Patients with Systemic AL, AA, and ATTR Amyloidosis (2004) (0)
Constitutive expression of the novel stat factor LIL-STAT in acute myeloid leukemia blasts. (1997) (0)
Disturbed protein and plasma membrane expression of flavocytochrome b(558), a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. (2002) (0)
migration of CD34+ cells from patients with myelodysplasia induced - derived factor-1 - contributes to an impairment of stromal cell Reduced activation of protein kinase B, Rac, and F-actin polymerization (2013) (0)
Only splenectomy induces a real complete remission in patients with idiopathic thrombocytopenic purpura. (1999) (0)
[Liver damage caused by nitrofurantoin]. (1981) (0)
STEM CELL DIVISION: DETERMINING THE SYMMETRY AND ROLE OF RAC PROTEINS (2018) (0)
Phase 2 study of car fi lzomib , thalidomide , and dexamethasone as induction / consolidation therapy for newly diagnosed multiple myeloma (2014) (0)
Identification of the TAK1-NF-kappa B Axis As Critical Regulator of AML Stem and Progenitor Cell Survival (2012) (0)
Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating capacity and hyperthermic sensitivity in mice mobilized with CTX plus G-CSF. (2000) (0)
Presence of mutant p53 increases stem-cell frequency and is associated with reduced binding to classical TP53 binding sites in cell lines and primary AMLs. (2022) (0)
A STUDY ON THE CLINICAL SIGNIFICANCE OF THE WHO AML SUBTYPE INV(3)(Q21Q26.2)/T(3;3)(Q21;Q26.2) AND VARIOUS OTHER 3Q CHROMOSOMAL ABNORMALITIES IN 6,819 AML CASES (2010) (0)
Autologous peripheral blood stem cell transplantation (Pbsct) In patients with lymphoma results in improved outcome and quality of life and cost reduction in comparison with bone marrow transplantation: The HOVON-22 study (2000) (0)
Extravascular retention after 48 hours of serum amyloid P component and semi-quantitative assessment of fat smears in patients with systemic amyloidosis (2001) (0)
p38 and ERK MAPKs Differentially Regulate Expansion and Differentiation of Human Cord Blood Derived CD34+ Cells during Neutropoiesis. (2006) (0)
Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels (2010) (0)
High expression of VEGF correlate with increased angiogenesis in acute myeloid leukemia. (2000) (0)
Unexpected consequences of sitosterolemia on platelet formation. (2006) (0)
Inhibitory effects of IL-4 on transcription factors involved in spontaneous IL-1 and IL-6 gene expression in acute myeloblastic leukemia cells (1996) (0)
A chronic myeloproliferative syndrome induced by the Polycomb Group gene Ezh2: mechanisms and interventions (2007) (0)
Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group (2013) (0)
In Vivo Treatment of AML Patients with High-Dose Simvastatin Inhibits Geranylgeranylation In AML Cells (2010) (0)
Characterization of signaling defects in granulocytes and myeloid precursor cells from myelodysplasia patients: its relation to apoptosis (2003) (0)
Measurable regression of systemic AL amyloid in fat tissue after response of serum free light chain (2010) (0)
DIFFERENTIAL REGULATION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 GENE-EXPRESSION IN MONOCYTIC CELLS (1993) (0)
Stem cell factor enhances erythropoietin-mediated STAT5 transactivation via the PKA-CREB pathway. (2002) (0)
Evaluation of the effects of AcSDKP and/or ET-18-OCH3 on the outcome of the hyperthermic purging of AML cells. (1998) (0)
Value of FDG-PET and somatostatin receptor scintigraphy for detecting multiple myeloma activity in patients with relapsing disease (2010) (0)
Endothelial Cells In Low-Risk MDS Show Ultrastructural Features of Enhanced Autophagy (2010) (0)
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. (2003) (0)
Subject Index, Vol. 63, 1980 (1980) (0)
Putative Autophagy Protein VMP1 Amplifies Protective Autophagy Under Stress Conditions in AML Cells (2017) (0)
Acute-phase response in patients given rhIL-3 after chemotherapy. (1992) (0)
impairs self-renewal and partially restores myelopoiesis in leukemic CD34+ stem/progenitor cells α Re-introduction of C/EBP (2013) (0)
RUNX1 Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding CD34(+) / CD33(+) / CD45RA(+) / CD123(+) Cell Population (2016) (0)
190 Efficacy of azacitidine and predictive factors for response in MDS and AML patients in the Dutch compassionate patient named programme (2011) (0)
α hematopoietic stem/progenitor cells involves downmodulation of C/EBP STAT5-induced self-renewal and impaired myelopoiesis of human (2013) (0)
HEMATOPOIESIS AND STEM CELLS Nonredundant and locus-speci fi c gene repression functions of PRC 1 paralog family members in human hematopoietic stem / progenitor cells (2013) (0)
PRC1 COMPLEX COMPOSITION DICTATES LOCUS-SPECIFIC POLYCOMB-MEDIATED REPRESSION IN HUMAN HEMATOPOIETIC STEM/PROGENITOR CELLS (2012) (0)
HOVON trial relapsed/progressive aggressive CD20+ NHL. A prospective randomized Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in (2013) (0)
[Hematopoietic growth factors as supportive treatment in drug-induced agranulocytosis]. (1993) (0)
The diagnostic performance of IL-8 as discriminator between fever episodes caused by bacterial infection or of nonbacterial origin in chemotherapy-related neutropenic patients. (1999) (0)
Mechanisms involved in HSC self-renewal and hematopoietic lineage commitment (2006) (0)
Is FDG-PET a better imaging tool than somatostatin receptor scintigraphy in relapsing multiple myeloma? (2012) (0)
Identification of Quantitative Trait Loci Regulating Steady State Hematopoiesis and Progenitor Mobilization in AKRB6F2 Mice. (2004) (0)
Genetic mouse models to predict haematopoietic recovery after chemotherapy: impact for the clinical practice (2000) (0)
Some observations in paroxysmal nocturnal haemglobinuraria and myelofibrosis (1983) (0)
Interactions between HSCs and their microenvironment (2006) (0)
A046 HOVON-50 Final Analysis of Thalidomide Combined with Adriamycin, Dexamethasone, and HDM (2009) (0)
Thrombopoietin-mediated activation of the mTOR/S6K/4E-BP signaling pathway is required for proliferation in megakaryocyte progenitors. (2004) (0)
cells + CD34 BMI1 collaborates with BCR-ABL in leukemic transformation of human (2012) (0)
Pre-Transplantation FDG-PET Is the Best Predictor for Outcome in Relapsed Lymphoma Patients Treated with Autologous Stem Cell Transplantation. (2004) (0)
Polycythaemia vera. (1992) (0)
Identification of USP7 as an essential component to maintain integrity and function of non-canonical PRC1.1 in leukemia (2018) (0)
status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to (2013) (0)
ATG5 and ATG7 Fulfill Essential and Non-Redundant Roles in Human Hematopoietic Stem/Progenitor Cells (2014) (0)
Ex-vivo expansion of human cord blood CD34+cells by overexpression of bmi-1. (2006) (0)
Fibroblast Growth Factors Regulate Stem Cell Functioning In Vitro and in Vivo. (2004) (0)
Deletion of the multidrug resistance protein 1 (MRP1) gene in acute myeloid leukemia patients with inversion 16: expression of MRP1 homologues (2001) (0)
University of Groningen Studies on megakaryopoiesis in patients with myelodysplasia and idiopathic thrombocytopenic purpura Houwerzijl, (2008) (0)
Familial thrombosis in a Dutch faily: inherited deficiency of antithrombin III. (1980) (0)
Long-Term Expansion and Self Renewal Is Contained in the CD34+, but Not the CD34-Subfraction of Nucleophosmin Mutated Acute Myeloid Leukemia Cells (2008) (0)
Molecular Mechanisms Involved in the Control of Differential Cytokine Expression in Human Monocytes (1997) (0)
THE SPONTANEOUS EXPRESSION OF IL-1-BETA AND IL-6 IS ASSOCIATED WITH SPONTANEOUS EXPRESSION OF AP-1 AND NF-KAPPA-B TRANSCRIPTION FACTOR IN ACUTE MYELOBLASTIC-LEUKEMIA CELLS (1994) (0)
Identification of Human Hematopoietic Stem Cell-Specific STAT5 Target Genes Involved in Self-Renewal and Transformation (2009) (0)
STAT5 Is a Negative Regulator of Megakaryopoiesis. (2006) (0)
The transcriptional and epigenetic targets of the AML associated oncofusion proteins AML1-ETO and PML-RAR alpha (2010) (0)
Downregulation of trombopoietin-induced proliferation, maturation and STAT5 tyrosine phosphorlylation by transforming growth factor beta in megakaryoblastic MO-7e cells. (2001) (0)
G(ANH)MTETRA, A NATURAL BACTERIAL-CELL WALL BREAKDOWN PRODUCT, INDUCES IL-1-BETA AND IL-6 EXPRESSION IN HUMAN MONOCYTES (1993) (0)
Dose dependent effects of STAT5 on proliferation, differentiation and self renewal of hematopoietic stem/progenitor cells. (2006) (0)
with hematopoietic cell turnover A genetic and genomic analysis identifies a cluster of genes associated (2013) (0)
The role of polycomb group proteins and KDM2B in leukemia (2016) (0)
Contents, Vol. 63, 1980 (1980) (0)
FLT-PET scanning in haematological disorders: a novel technique to visualize the bone marrow compartment. (2006) (0)
MMP-2 protein expression in AML-blasts is strongly correlated with an inversion of chromosome 16. (2003) (0)
Constitutive STAT3 Tyr705 and Ser727 phosphorylation in AML is caused by autocrine secretion of IL-6. (1999) (0)
Interleukin-15 enhances the expression of interferon-γ and interleukin-4 in activated human T lymphocytes by post-transcriptional mechanisms (1996) (0)
Loss of ASXL1 Triggers an Apoptotic Response in Human Hematopoietic Stem and Progenitor Cells (2014) (0)
Randomized P lacebo-Controll ed T rial o f G r anulocyte- M a crophage C olony-Stimulati ng F actor i n P atients W ith Chemotherapy-Rel ated F ebrile N e utropenia (1996) (0)
Patients with AL amyloidosis treated with VAD followed by high dose melphalan and autologous stem cell transplantation (2001) (0)
Cycling activity and hyperthermic sensitivity of peripheral blood stem cells depends on the mobilization protocol. (1999) (0)
Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial (2019) (0)
Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib (2013) (0)
Characterization of β-adrenoceptor subtype(s) involved in the regulation of cytokine gene expression in activated human T lymphocytes (1997) (0)
Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group (2014) (0)
Diagnostic accuracy and prognostic value of I-123-labeled SAP body retention in patients with amyloidosis (2006) (0)
High-Dose Therapy in AL Amyloidosis (2008) (0)
Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial (2012) (0)
Inhibition of Long-Term Expansion in a Subgroup of Acute Myeloid Leukemia Samples by Dasatinib (2008) (0)
Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy. (2006) (0)
older age : a randomized phase 2 trial of the Dutch-Belgian Cooperative Addition of bevacizumab to chemotherapy in acute myeloid leukemia (2012) (0)
Serine phosphorylation of STAT5 in response to interleukin-7 and T cell activation (1998) (0)
Interteukin-7 induces the activation of the MKK4-JNK and MKK6-ERK6 pathways via Rac1 in human mature T lymphocytes (1997) (0)
A SYNDROME OF SEVERE UPPER ABDOMINAL-PAIN, ELEVATED LIVER-ENZYMES, INTRAVASCULAR COAGULATION AND (PRE) ECLAMPTIC LIVER-LESIONS IN THE 3RD TRIMESTER OF PREGNANCY WITHOUT OR WITH ONLY MILD HYPERTENSION (1984) (0)
and idarubicin with acute promyelocytic leukemia treated with all-trans retinoic acid Causes and prognostic factors of remission induction failure in patients (2013) (0)
Muc1 overexpression in human CD34 positive hematopoietic cells results in increased stem and progenitor frequencies (2007) (0)
Expression ofMultidrug Resistance ^ Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia (2005) (0)
Abstracts of papers and posters Clinical Pharmacological Meeting (1993) (0)
Effects of overexpression of the SH2-containing inostitol phosphatase ship in erythroid cells during growth factor deprivation. (2000) (0)
Combining Metabolome, Transcriptome and Proteome Approaches to Identify Vulnerabilities in AML: Role of Pdks (2018) (0)
A Comprehensive Dna Test For The Detection Of Translocations In Acute Leukemia (2017) (0)
The Polycomb Gene BMI1 Collaborates with BCR-ABL in Leukemic Transformation of Human Cord Blood CD34+ Cells. (2008) (0)
Muc1 expression identifies human self-renewing stem/progenitor populations and is elevated in AML CD34+ cells (2007) (0)
Prostaglandin E2 modulates IL-5 gene expression activated human T lymphocytes depending on the costimulatory signal (1997) (0)
Factors Controlling Expansion and Maturation of Haematopoietic Progenitor Cells (2003) (0)
Hematopoietic Stem Cells, but Not Progenitors, Are the Exclusive Target for STAT5-Induced Long-Term Self-Renewal (2008) (0)
Diagnostic Value of Free Kappa and Lambda Light Chains in Fat Tissue of Patients with Systemic AL Amyloidosis (2004) (0)
HSP27 protects malignant hematopoietic cells against VP-16-induced apoptosis through modulation of p38 and C-JUN. (2004) (0)
Validation and implementation of a custom 21-gene panel next-generation sequencing assay for myeloid neoplasms (0)
AML-derived IL-8 production supports angiogenesis. (1999) (0)
Abstract 2361: Bone Marrow Dysfunction In Chronic Heart Failure Patients Contributes To Impaired Erythropoiesis (2008) (0)
Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment: subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma (2011) (0)
The impact of haematopoietic growth factors on supportive care in clinical oncology : With special attention to potential tumour cell contamination in the stem cell harvest (1998) (0)
Bone Microenvironment Overcomes TRAIL Resistance Mediated by D 269 H / E 195 R to Osteoprotegerin ( OPG ) Apoptosis-inducing Ligand ( rhTRAIL ) Tumor Necrosis Factor-related Decreased Affinity of Recombinant Human Cell (2013) (0)
Population based genotyping of human leukocyte antigen (HLA) in Hodgkin lymphoma (2004) (0)
Improving chemotherapy efficacy in acute myeloid leukemia patients by modulation of dysfunctional cholesterol metabolism (2006) (0)
Stress-induced epigenetic remodeling of polycomb target genes (2017) (0)
In vitro generation of long-term repopulating hemotopoietic stem cells by FGF-1. (2002) (0)
Effect of cotreatment with statins and farnesyltranferase inhibitors on acute myeloid leukemia cells (2008) (0)
In vitrodevelopment of haemopoietic progenitors in myelodysplastic syndromes (MDS) (1999) (0)
Distinct Gene Expression Profiling in AML in Elderly Versus Younger Patients. (2008) (0)
Decreased PU.1 and Enhanced CITED2 Cooperate To Maintain Self-Renewal In Hematopoietic Stem/Progenitors (2013) (0)
First Interim Analysis of HOVON 76 (2009) (0)
Complex clustered gene expression patterns in hematopoietic stem cells (2002) (0)
Title : Establishing a human leukemia xenograft mouse model (2016) (0)
Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters (1996) (0)
Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis (2014) (0)
Autologous Stem Cell Transplantation Induces a Phenotypical Shift From CMP to GMP Progenitors, Reduces Clonogenic Potential and Enhances in Vitro and In Vivo Cycling Activity Defined by 18f-FLT PET Scan. (2009) (0)
CITED2 MODULATES DIFFERENTIATION AND PROLIFERATION OF NORMAL AND LEUKEMIC HEMATOPOIETIC STEM AND PROGENITOR CELLS DOWNSTREAM OF PU.1 (2011) (0)
Identification of leukemia enriched plasma membrane proteins allows prospective isolation and analysis of distinct subclones providing new opportunities for diagnosis and targeting of acute myeloid leukemia (2016) (0)
Synergistic STAT5 Transactivation by SCF and TPO in megakaryocytic MO7e cells. (2003) (0)
CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells (2015) (0)
The role of autophagy in hematopoietic stem cell functionality and development of myelodysplasia (MDS) (2010) (0)
Relationship between in vitro expansion of megakaryocytic progenitor cells and platelet recovery. (2000) (0)
Interleukin-7 differentially modulates the expression of interferon-gamma and IL-4 in activated human T-lymphocytes by transcriptional- and post-transcriptional mechanisms (1995) (0)
in acute myeloblastic leukemia The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells (2011) (0)
A "pre-induction course" with AraC and VP16 and with MTX for high risk improves treatment outcome in adult acute lymphoblastic leukemia (ALL). (2003) (0)
Diagnostic accuracy and prognostic value of I-123-labeled serum amyloid P component body retention in patients with amyloidosis (2008) (0)
Erythroid precursors from patients with low-risk Myelodysplasia demonstrate ultrastructural features of autophagy. (2006) (0)
fibrinolysis inhibitor alpha-2-antiplasmin in blood The mutual relationship between the two molecular forms of the major (2011) (0)
NF-kappa B and MCL-1 Are Important Determinants for the Effectiveness of Bortezomib In CD34(+) AML Versus CD34(-) AML Cells (2011) (0)
Differential Localization Of RAC1 and RAC2 Reflects Their Specific Functions In Normal and Leukemic Human Hematopoietic Stem/Progenitor Cells (2012) (0)
Declined presentation: Decreased PU.1 and enhanced cited2 cooperate to maintain self-renewal (2013) (0)
Lymphocyte characteristics and function in paroxysmal nocturnal haemoglobinuria (1983) (0)
Characterization of beta-adrenoceptor subtype(s) involved in the regulation of cytokine gene expression in activated human T lymphocytes (1996) (0)
The Dutch Lenalidomide Named Patient Program (2009) (0)
Randomized induction and post induction therapy in adult patients (≤ 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score ≥ 1.5 (2005) (0)
Recurrent intestinal haemorrhages caused by a lipoma in the ileocaecal valve in a patient with Von Willebrand's disease. (1980) (0)
Plasma rather then leukocytes are responsible for the most common adverse effects of platelet concentrates. (2001) (0)
The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio (2014) (0)
Behavior of the murine stem cell compartment after different scenarios of chemotherapy and growth factor treatment (1999) (0)
Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study (2020) (0)
Lymphoma Immunodeficient Mouse Model of Human Non-Hodgkin ' s Tumor Growth in a Nonobese Diabetic / Severe Combined Mobilized Human CD 34 + Hematopoietic Stem Cells Enhance (2001) (0)
University of Groningen Inhibition of the Transforming Growth Factor β ( TGFβ ) Pathway by Interleukin-1 β Is Mediated through TGFβ-activated Kinase 1 Phosphorylation of SMAD 3 (2018) (0)
Different scenarios of chemotherapy and growth factor treatment and the hemopoietic stem cell compartment. (1999) (0)
Disturbed neutrophil functioning and signal transduction in MDS (2006) (0)
University of Groningen Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock Azkanaz, (2019) (0)
MYELOID NEOPLASIA The TAK 1-NFk B axis as therapeutic target for AML (2014) (0)
In vitro purging of human acute myeloid leukemic stem cell subsets with a combined hyperthermia/ET-18-OCH3 treatment. (2001) (0)
p38MAPK Inhibits Neutrophil Development through Phosphorylation of C/EBP alpha on Serine 21 (2008) (0)
The influence of crooslinking by factor XIII on lysis of whole and diluted blood clots : avoidance of interference by anticoagulants and role of α_2-antiplasmin. Abstract (1983) (0)
In vitro expansion of Multiple Myeloma clonally related cells (1998) (0)
Phenotypic and genetic analysis of stem cell number find mobilization potential in genetically distinct mouse strains (2002) (0)
Enforced expression of BMI-1 facilitates ex-vivo expansion of human cord blood CD34(+) cells (2007) (0)
Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group (2013) (0)
Alternative Approaches to Prevention of Alloimmunisation: A Virtue of Reality? (1999) (0)
Identification of USP7 as druggable target in non-canonical PRC1.1 for human leukemias (2016) (0)
Various Other 3 q Abnormalities in Acute Myeloid Leukemia (2010) (0)
Daratumumab in transfusion‐dependent patients with low or intermediate‐1 risk myelodysplastic syndromes (2021) (0)
The enhancement of the therapeutic index of a hyperthermic purging protocol for AML cells by AcSDKP (Goralatide) (1997) (0)
Diagnostic accuracy and prognostic value of I-123-labeled serum amyloid P component retention in amyloidosis. (2006) (0)
Paroxysmal nocturnal haemoglobinuria. (1983) (0)
PS996 TCF4 IS IMPORTANT FOR MUTANT RUNX1-MEDIATED CELL IMMORTALIZATION AND PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Edo Vellenga?

Edo Vellenga is affiliated with the following schools:

Edo Vellenga's Academic­Influence.com Rankings

Edo Vellenga's Degrees

Similar Degrees You Can Earn

Why Is Edo Vellenga Influential?

Edo Vellenga's Published Works

Published Works

What Schools Are Affiliated With Edo Vellenga?

Edo Vellenga's AcademicInfluence.com Rankings